Immuno Cure: HK Biotech Firm Gears up for IPO with $12m Funding

HK Biotech Firm Gears up for IPO with $12m Funding

Immuno Cure focuses on R&D of immunotherapies for cancers, inflammatory and infectious diseases

The Hong Kong Science Park-based biotech company will use the new money to speed up the development of DNA vaccines and antibodies and get ready for a local initial public offering (IPO).

Funding Details

  • Funding amount: US$12,000,000
  • Lead investor: AEF Greater Bay Area Fund
  • Stage: Series A
  • Source

Immuno Cure was started in 2015, and it focuses on cancer immunotherapies as well as immunotherapies for illnesses that cause inflammation and infections. Immunotherapy is a medicine that uses the body’s immune system to find and kill cancer cells.

The company is currently testing ICVAX and ICCOV, which are both potential DNA vaccines.

Immuno Cure’s CEO, Xia Jin, said that the company will keep working on research and development for new vaccine technologies “to improve our arsenal against cancers and infectious diseases.”

Also Read: Twitter Rebranding

The Hong Kong Science and Technology Parks Corporation gave the company a grant of $910,000 in June so that it could start a clinical study with the University of Hong Kong. The goal of the study is to find out how well a booster DNA vaccine against Covid-19 works.

More Details

Immuno Cure BioTech


Stage Amount (US$) Investors
Series A 12 million AEF Greater Bay Area Fund
Total 12 million



Follow Instagram, Youtube, Twitter

One thought on “Immuno Cure: HK Biotech Firm Gears up for IPO with $12m Funding

Leave a Reply

Your email address will not be published. Required fields are marked *